StockData
Skye Bioscience, Inc. logo

Skye Bioscience, Inc. (SKYE) stock

SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30
$1.00−0.06 (-6.10%)

Close on Nov 17, 2026Market cap $35.42MP/E –Yield –

Skye Bioscience operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Skye Bioscience's operating income for the twelve months ending Jun 30, 2026 was -$51.90M. For fiscal 2025 it was -$58.16M. The highest annual figure on record is $4.12K in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$58.16M–
FY2024Dec 31, 2024-$30.19M–
FY2023Dec 31, 2023-$34.74M–
FY2022Dec 31, 2022-$18.31M–
FY2021Dec 31, 2021-$7.85M–
FY2020Dec 31, 2020-$6.29M–
FY2019Dec 31, 2019-$6.63M–
FY2018Dec 31, 2018-$4.69M–
FY2017Dec 31, 2017-$3.86M–
FY2016Dec 31, 2016-$4.47M–
FY2015Dec 31, 2015-$4.32M–
FY2013Oct 31, 2013-$3.78K-191.9%
FY2012Oct 31, 2012$4.12K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.06M–
Q1 FY2026Mar 31, 2026-$12.67M–
Q4 FY2025Dec 31, 2025-$14.90M–
Q3 FY2025Sep 30, 2025-$13.26M–
Q2 FY2025Jun 30, 2025-$18.24M–
Q1 FY2025Mar 31, 2025-$11.76M–
Q4 FY2024Dec 31, 2024-$10.67M–
Q3 FY2024Sep 30, 2024-$4.97M–
Q2 FY2024Jun 30, 2024-$8.41M–
Q1 FY2024Mar 31, 2024-$6.15M–
Q4 FY2023Dec 31, 2023-$4.09M–
Q3 FY2023Sep 30, 2023-$24.71M–
Q2 FY2023Jun 30, 2023-$2.84M–
Q1 FY2023Mar 31, 2023-$3.10M–
Q4 FY2022Dec 31, 2022-$9.28M–
Q3 FY2022Sep 30, 2022-$2.92M–
Q2 FY2022Jun 30, 2022-$3.22M–
Q1 FY2022Mar 31, 2022-$2.89M–
Q4 FY2021Dec 31, 2021-$2.46M–
Q3 FY2021Sep 30, 2021-$1.82M–
Q2 FY2021Jun 30, 2021-$1.83M–
Q1 FY2021Mar 31, 2021-$1.74M–
Q4 FY2020Dec 31, 2020-$1.32M–
Q3 FY2020Sep 30, 2020-$1.54M–
Q2 FY2020Jun 30, 2020-$1.22M–
Q1 FY2020Mar 31, 2020-$2.21M–
Q4 FY2019Dec 31, 2019-$1.84M–
Q3 FY2019Sep 30, 2019-$1.50M–
Q2 FY2019Jun 30, 2019-$1.77M–
Q1 FY2019Mar 31, 2019-$1.52M–
Q4 FY2018Dec 31, 2018-$1.32M–
Q3 FY2018Sep 30, 2018-$1.05M–
Q2 FY2018Jun 30, 2018-$1.08M–
Q1 FY2018Mar 31, 2018-$1.25M–
Q4 FY2017Dec 31, 2017-$986.52K–
Q3 FY2017Sep 30, 2017-$761.63K–
Q2 FY2017Jun 30, 2017-$730.93K–
Q1 FY2017Mar 31, 2017-$1.38M–
Q4 FY2016Dec 31, 2016-$912.06K–
Q3 FY2016Sep 30, 2016-$856.15K–

More Skye Bioscience figures

See a number that looks wrong?